Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Global Blood Therapeutics (GBT) Data 'Exceeded Our High Expectations' - Cowen

Global Blood Therapeutics (GBT) Gains on Positive Results from Ongoing Sickle Cell Drug Trial

June 10, 2016 9:07 AM EDT

Global Blood Therapeutics (NASDAQ: GBT) is gaining 21% pre-open trade after the company... More

Global Blood Therapeutics (GBT) Announces New Results from Ongoing Phase 1/2 GBT440-001 Study in Sickle Cell Disease

June 10, 2016 8:01 AM EDT

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced new results from its ongoing Phase 1/2 GBT440-001 study in sickle cell disease (SCD) that further support the company's plans to develop GBT440 as a potential disease-modifying therapy for SCD. The data being presented today at the European Hematology Association's (EHA) 21st Congress in Copenhagen include a poster presentation of... More